Early and Sustained Asthma Control and Remission in Real‐World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: <scp>XALOC</scp> ‐2
Real-world patients receiving benralizumab showed early and sustained improvements in asthma symptoms, regardless of previous biologic use. More than a quarter of patients achieved clinical asthma remission after 1 year of benralizumab treatment.
Authors
- Thomas Rothe (ORCID: https://orcid.org/0000-0003-0598-1306)
- Benjamin Emmanuel (ORCID: https://orcid.org/0000-0003-1769-9826)
- Andrew Menzies‐Gow (ORCID: https://orcid.org/0000-0001-9707-4986)
- Marek Lommatzsch (ORCID: https://orcid.org/0000-0002-9305-9348)
- Trung N. Tran (ORCID: https://orcid.org/0000-0001-8003-7601)
- An Herreman
- Claudio Schuoler
- Anat Shavit
- Sheena Kayaniyil (ORCID: https://orcid.org/0000-0003-0239-9580)
- Tanja Plate (ORCID: https://orcid.org/0000-0001-8697-6458)
- Lieven Dupont (ORCID: https://orcid.org/0000-0003-3961-1522)
- Erika Dianne Penz (ORCID: https://orcid.org/0000-0003-2610-8450)
- David Cohen
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of Saskatchewan (CA)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- Kantonsspital Graubünden (CH)
- AstraZeneca (Canada) (CA)
- AstraZeneca (United States) (US)
- AstraZeneca (Germany) (DE)
- University of Rostock (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1111/cea.70162
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca